ArticleInternational ophthalmology2026
Central subfield thickness changes and factors associated with OCT-confirmed cystoid macular edema after slow-coagulation transscleral cyclophotocoagulation for glaucoma.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo quantify serial central subfield thickness (CSFT) changes after slow-coagulation transscleral cyclophotocoagulation (SC-TSCPC) for glaucoma, estimate the incidence of OCT-confirmed cystoid macular edema (CME), and explore baseline factors associated with CME, including diabetes and prior diabetic macular edema.
methodsRetrospective cohort of 31 eyes undergoing SC-TSCPC for glaucoma with OCT imaging preoperatively and postoperatively at 1, 3, 6, 9, and 12 months and at last follow-up (range 9-30 months). OCT-confirmed CME was defined as cystoid intraretinal changes on OCT; increased CSFT alone was not classified as CME. Changes over time were assessed with non-parametric repeated-measures testing, and subgroup comparisons were exploratory and univariate because of the small sample size.
resultsMean baseline CSFT was 279 ± 25 um and peaked at 355 ± 153 um at 1 month, then declined to 293 ± 25 um at 12 months (p < 0.001 across visits). Mean CSFT at last follow-up remained higher than baseline (294 ± 25 vs. 279 ± 25 um; p < 0.001). OCT-confirmed CME developed in 8/31 eyes (25.8%), first detected at 1-6 months (mean 2.1 ± 1.8). Eyes that developed OCT-confirmed CME had higher preoperative CSFT than eyes without CME (311 ± 21 vs. 267 ± 15 um; p < 0.001). In exploratory univariate analyses, OCT-confirmed CME occurred more frequently in eyes with diabetes mellitus (p = 0.031) and prior diabetic macular edema (p < 0.001). Mean intraocular pressure decreased from 36.1 ± 9.0 to 15.2 ± 3.6 mmHg at 12 months (p < 0.001). Mean corrected distance visual acuity (CDVA) changed from 0.90 ± 0.90 logMAR preoperatively to 1.02 ± 0.85 logMAR at last follow-up (p = 0.004), and CDVA at last follow-up did not differ between eyes with and without OCT-confirmed CME (p = 0.992).
conclusionSC-TSCPC was associated with a transient postoperative increase in CSFT and a clinically relevant incidence of OCT-confirmed CME. In this small retrospective cohort, higher preoperative CSFT and diabetes-related retinal disease identified a subgroup with greater observed CME frequency, but these findings should be interpreted as exploratory associations rather than independent risk factors. Postoperative OCT surveillance may help identify early anatomic edema, particularly in higher-risk eyes.
Indexed as
Identifiers
42159842What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.